New drug cocktail shows promise for tough childhood leukemia
NCT ID NCT05192889
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 37 times
Summary
This early-phase trial is testing whether adding two targeted drugs, venetoclax and navitoclax, to standard chemotherapy can help children whose acute lymphoblastic leukemia has come back or not responded to treatment. About 35 children will receive the combination to see if it can wipe out hidden leukemia cells. The goal is to find the best dose and measure how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax and navitoclax (oral drugs) combined with standard chemotherapy drugs
What this could lead to
If successful, this could offer a new treatment option for children whose leukemia has returned or not responded to standard therapy, potentially improving remission rates.
What could go wrong
This is an early-phase trial with only 35 participants, so results may not apply broadly. The combination drugs can cause side effects like low blood counts and infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.